May 24, 2021, 5:00 a.m. ET
Credit.Chloe Cushman
By Candida Moss
Ms. Moss is a professor of theology at the University of Birmingham in the U.K. who is based in New York. She also studies disability theory and is a kidney transplant recipient.
âWhen can we meet?â As more people are vaccinated, my inbox grows ever more hopeful. Emails from conference organizers, employers, friends, family and businesses promise that we will soon âget back to normalâ and put the dark shadow of the pandemic behind us. Now that the Centers for Disease Control and Prevention has determined that masks are no longer necessary for the vaccinated, the spring has brought with it an optimistic news cycle that eagerly anticipates the post-Covid world.
Share: Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer
MIAMI, May 24, 2021 (GLOBE NEWSWIRE) Veru Inc. (NASDAQ:VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that two abstracts were accepted for presentation at the 2021 American Society of Clinical Oncology Annual Meeting which will be held virtually from June 4-8, 2021.
Young adults and adolescents who get COVID-19 may also exhibit symptoms of a complex, multisystem disorder previously known as chronic fatigue syndrome, three new case studies show.
With more of this age group being treated for COVID-19, clinicians are concerned they will start showing post-COVID or “long haul“ symptoms from their bouts with the virus.
The review in
Frontiers in Medicineprovides some of the first evidence that myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), may be one serious post-COVID problem.
“In the three patients studied all of whom had confirmed or highly probable COVID-19 infections early in the pandemic we observed ME/CFS-like symptoms within the first two weeks of illness,” says Peter Rowe, professor of pediatrics at Johns Hopkins University School of Medicine and director of the Chronic Fatigue Clinic at Johns Hopkins Children’s Center. “At six months following their illness, all three still met the criteria for being diagnosed
Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.
Novel Immunotherapy Relatlimab in Advanced Melanoma medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.